Australia markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4300+0.0800 (+1.84%)
At close: 04:00PM EDT
4.4900 +0.06 (+1.35%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3500
Open4.3400
Bid4.3700 x 1300
Ask4.5000 x 1800
Day's range4.2000 - 4.4550
52-week range2.8700 - 8.5800
Volume3,394,976
Avg. volume3,876,939
Market cap455.949M
Beta (5Y monthly)0.99
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

    SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions

  • Business Wire

    bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

    SOMERVILLE, Mass., January 18, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be c

  • Business Wire

    bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

    SOMERVILLE, Mass., January 09, 2023--bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT.